Saba Shabir et al



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.2604592

Available online at: <u>http://www.iajps.com</u>

Research Article

TREATMENT OF IBS-D CASES THROUGH RIFAXIMIN

¹Dr. Saba Shabir, ²Dr. Qamar Gul, ³Dr. Jawariya Zia

¹Nishtar Medical University, Multan, ²Allama Iqbal Medical College, Lahore, ³RMC Sir Ganga

Ram, Hospital, Lahore.

Article Received: January 2019	Accepted: February 2019	Published: March 2019

Abstract:

Objectives: Our aim was to observe the outcome of Rifaximin for the cases having IBS-D.

Study design: A descriptive case control study.

Place and Duration: We conducted this study for a time duration of 12 months starting from the month of January, 2018 to month of December, 2018 at medical OPD of Services Hospital in Lahore.

Methodology: A total number of 30 patients matching the Rome II diagnostic criteria for IBS were selected for the study amongst which there were 12 males and 18 females. All selected patients were having age of more than 14 years. Linkert scoring system was used for selection of patients as according to this system only those patients were selected who rated the average daily amount of abdominal pain and bloating as a score of 2 or more than two. Mean makeup of stools typically per day is calculated through 5-point scale stool regularity. All those patients who were having colonic malignancy, kidney failure, chronic liver disease, human immune defect virus toxicity, hyper thyroids, hyper thyroids, high blood sugar, instigative bowel ailment and its descriptions, IBS major constipation, cases diagnosed through anti spasmodic, anti-psychotics, probiotics, anti-narcotics and probiotics or other antibiotic in last 14 days were not included in the study.

Results: A total number of 30 cases were referred to the OPD for the analysis of IBS-D out of which 18 were females and 12 were males with the percentage of 60.0% and 40.0% respectively. Cases have 13-38 years of age. All the cases were suggested to use Tablet Rifaximin 550 mg in a rotation of three within 24 hours for a period of two weeks and directed to use the Li Kert scale and 5-point scale for the regularity and frequency level of diarrhea and its treatment for the abdominal pain, bloating and stool constancy. Cases were evaluated to consult again for the checkup after two weeks on the on the 15^{th} day and after 60 days again. As an observation of 30 diagnosed cases out of which 18 cases with the percentage of 60.0% got relief in their IBS-D ailment during the treatment within two weeks but only 12 cases with the percentage of 40.0% out of 18 cases with the percentage of 60.0% which reacted to the diagnosis through Rifaximin in a duration of 60 days were found regular cured from the indication of this disease whereas 6 cases with the percentage of 20.0% still have progressed IBS-D. Because of setup in level of diarrhea, 2 cases with the percentage of 6.0% left the treatment on the 3^{rd} day of diagnosis. Females were 11 with the percentage of 61% from the 18 reacted cases and were older in age comparatively. Details are shown in the below table.

Conclusion: According to the results of our study, Rifaximin was observed to deliver most liberation in the indications and treatment of IBS-D Key Words: Diarrhea, Irritable bowel syndrome IBS and Rifaximin.

Corresponding author: Dr. Saba Shabir, *Nishtar Medical University, Multan.*



Please cite this article in press Saba Shabir et al., **Treatment Of Ibs-D Cases Through Rifaximin.,** Indo Am. J. P. Sci, 2019; 06(03).

Saba Shabir et al

INTRODUCTION:

A functional gastrointestinal ailment which is categorized with the infections of bloating, altered bowel function and abdominal pain is called irritable bowel syndrome (IBS). Its is transformed due to lack of biochemical or physical seditious and these indications are habitual mostly [1]. The analysis is continued for the causes of IBS. It is proposed by a irregular consciousness several that of gastrointestinal area reacts for numerous inducements comprising some kinds of meals, stress, expansion of G.I area [2] and definite substances. The instinctual hyper sensation was believed by several to be a factor of IBS. The dis-connectivity of Brain and GI area was disagreed by several specialists. The variations of intestinal microbiota are thought by some of abnormalities of IBS [3]. IBS are thought to be diagnosed through antibiotics [4]. Rifaximin is unsystemic verbal extensive antibacterial spectrum to react to instinctive with least nonbacterial conflicts [5]. It is observed that variation of intestinal microflora is factor of IBS and it is diagnosed through verbal antibacterial drugs got through reactions of Rifaximin in cases of IBS-D and its analysis.

startingfrom the month of January, 2018 to month of December, 2018 at medical OPD of Services Hospital in Lahore. A total number of 30 patientsmatchingthe Rome II diagnostic criteria for IBS were selected for the study amongst which there were 12 males and 18 females. All selected patients were having age of more than 14 years. Linkert scoring system was used for selection of patients as according to this system only those patients were selected who rated the average daily amount of abdominal pain and bloating as a score of 2 or more than two.Mean makeup of stools typically per day is calculated through 5-point scale stool regularity. All those patients who were having colonic malignancy, kidney failure, chronic liver disease, human immune defect virus toxicity, hyper thyroids.hyper thyroids, high blood sugar, instigative bowel ailment and its descriptions, IBS major constipation, cases diagnosed through anti spasmodic, anti-psychotics, probiotics, anti-narcotics and probiotics or other antibiotic in last 14 days were not included in the study.

RESULTS:

A total number of 30 cases were referred to the OPD for the analysis of IBS-D out of which 18 were females and 12 were males with the percentage of 60.0% and 40.0% respectively.

METHODOLOGY:

This descriptive case control study was held at Services Hospital, Lahore for the duration of one year

Table No 01: Gender Distribution

Gender	No of cases	Percentage
Male	12	40.0%
Female	38	60.0%



Saba Shabir et al

Cases have 13-38 years of age. All the cases were suggested to use Tablet Rifaximin 550 mg in a rotation of three within 24 hours for a period of two weeks and directed to use the Li Kert scale and 5-point scale for the regularity and frequency level of diarrhea and its treatment for the abdominal pain, bloating and stool constancy. Cases were evaluated to consult again for the checkup after two weeks on the on the 15th day and after 60 days again. As an observation of 30 diagnosed cases out of which 18 cases with the percentage of 60.0% got relief in their IBS-D ailment during the treatment within two weeks but only 12 cases with the percentage of 60.0% which reacted to the diagnosis through Rifaximin in a duration of 60

days were found regularly cured from the indication of this disease whereas 6 cases with the percentage of 20.0% still have progressed IBS-D. Because of setup in level of diarrhea, 2 cases with the percentage of 6.0% left the treatment on the 3rd day of diagnosis. Females were 11 with the percentage of 61% from the 18 reacted cases and were older in age comparatively. Old age and female cases as compared to young age and male were observed to be diagnosed through Rifaximin most reactively. As a number of 7 males and 11 female cases with the percentage of 39.0% and 61.0% respectively reacted from total of 18 countered cases and observed comparatively older in age from 28years to 32years.



Table No 02: Improvement statistics

DISSCUSSION:

The habitual gastrointestinal disorder of indefinite etiology is called IBS and described as the occurrence of abdominal infection and diversified bowel performance in the clinical indications like expressive weight loss and anemia [6]. Cases fluctuated constipation which were available with the diarrhea. By involvement of visceral hypersensitivity numerous mechanisms were analyzed. Through lactulose hydrogen breath analysis, the GI area swelling and microbial infestation was observed [7]. The Occurrence of lactulose hydrogen breath analysis with the percentage of 14.0% up to 78.0% was positively observed [8]. Rifaximin was suggested to react with

micro-organisms affected with IBS indications during the analysis at Mayo Hospital by bearing in mind this pathogenesis. Rifaximin obtained is semi synthetically from Rifamycin consisting of extra benzimidazole ring for avoiding Rifaximin to be meticulously immersed [9]. Creatures gram positive or negative which are aerobic or anaerobic respectively are treated by this [10]. It reacts through the prevention of requisite B-sub unit of bacterial DNA attached to RNA polymerase by the synthesis of bacterial protein. Therefore, it prevents the commencement of chain configuration in RNA synthesis. The sub therapeutic absorptions of tissue toxicity and supplements and bacteria pathogenesis are deceptively altered by Rifamycin [11]. Rifaximin is positively observed as a definite conclusion to have reaction to fundamental infections of IBS and modification of intestinal microbiota is related to it [12]. The bacterial evolution in the cases of IBS are presented by me as the analysis of the Posserud and Ford Ac [13,14].

Studies done by the Ford AC [13]and Posserud [14] also showed bacterial over growth in patients with irritable bowel syndrome. The signs of IBS increase and decrease in various patients of IBS while they undergo through this disease in their life stages. Rifaximin medicates the special cases of IBS-D for an extended time as compared to the newly stated medication by Chey through present diagnosis like the alteration of diet and fiber complements to various cases which got un-necessary outcomes because the signs of IBS start again as the medication is stopped. During our analysis out of 30 cases, 12 cases presented to get a significant outcome even after the stoppage of diagnosis for 2 months and 18 cases presented relief in their bloating, diarrhea and abdominal pain which are medicated through Rifaximin. Regulation of breath analysis observed through the oral use of Rifaximin was presented by Pimentel by his analyzation [15]. Treatment through Rifaximin presented positive outcomes in the signs of IBS within two weeks as the same analysis made by Palsson and Schey R [16,17]. Analysis by Hertig VL and Trinkley KE was the same as our analysis which presented the treatment of IBS infections got positive outcomes through Rifaximin and it is more affective to female cases as compared to male cases [18]. Fumi et al did same analysis as the conclusion presented in our analyzation that instead of young case, old cases were found to have more impact of Rifaximin [19].

CONCLUSION:

IBS-D cases which are suffering from critical fatigues, having unhappy type of living and got absentfrom their work can be diagnosed through Rifaximin as it enhances the way of living. However, IBS is mostly unlikable disease but it may not produce complexity.

REFERENCES:

- 1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130:1480-91.
- Brandt LJ, Chey WD, Foxx Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104: S1-35.
- 3. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel

symptoms. GastrointestEndose Clin N Am 2009; 19: 141-50

- 4. Rivkin A, Gim S. Rifaximin. A new therapeutic indication and future directions. Clin Ther 2011; 33(7): 812-27.
- Menees SB, Maneerattanna-porn M, Kim HM, Chey WD. The efficacy and safety of Rifixamin for the irritable bowel dyndrome. Am J Gastroenterol 2012; 107:28-35.
- Chitkara DK, Van Tilburg MA, Blois Martin N et al. Early life risk factors that contribute to irritable bowel syndrome in adults. Am J Gastroenterol 2008;103:765-74.
- Meyrat P, Safroneeva E, Schoepfer AM. Rifaximine treatment for irritable bowel syndrome with positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharma Col Ther 2012; 36(11-12): 1084-93.
- Parodi A, Dulbecco P, savarino E, Gianni EG, Bodini G, Corbo M. Positive glucose breath testing is more prevalent in patients with controls of similar age and gender distribution. J Clin Gastroenterol 2009; 43(10): 962-6.
- 9. Mortini S, Boneci C, Corboni G, Donati A, Rossi C Solution structure of Rifaximin and its synthetic derivative determined by NMR and theroretical simulation methods. Bioorg Med Chem 2004; 12: 2163-72.
- 10. Dupont HL, Jiang ZD. Influence of Rifaximin treatment on susceptibility of intestinal gramnegative flora and enterococci. Clin Microbiol Infect 2004; 10: 1009-11
- Baker DE. Rifaximin. A non-absorbed oral antibiotic. Rev Gastroenterol Discord. 2005; 5:19-30.
- 12. Schmulson M, Chang L. The treatment of functional abdominal bloating and distension. Aliment pharmacolTher. 2011; 33(10): 1071-86.
- 13. Ford AC, Spiegel BMR, Talley NJ, Macyyedi P. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 1279-86.
- 14. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal overgrowth with irritable bowel syndrome. Gut 2007; 56: 802-8.
- 15. Pimental M, Moralesw, Chua K, Barlow G. Weitsman S, Kin G. et al. Effects of Rifaximin treatment and retreatment in non-constipated IBS subjects. Dig Dis Sci 2011; 56(7): 2067-72.
- Schey R, Rao SS. The role of Rifaximin therapy in patients with irritable bowel syndrome without constipation. Rev Gastroenterol Hepatol. 2011; 5(4):461-4.
- 17. Palsson OS, Baggish JS. Turner MJ, White head

WE. IBS patients show frequent fluctuations between loose/watery and hand lumpy stools: implication for treatment. AMJ Gastroenterol 2012; 107(2): 286-95.

- Hertig VL, Cain KC, Jarrett ME, Burr RL. Daily stress and gastrointestinal symptoms in woman with irritable bowel syndrome. Nurs Res. 2007; 56(6) 399-406.
- 19. TrinkleyKe, Nahata MC. Treatment of irritable bowel syndrome. J Clin Pharm Ther 2011; 36(3): 275-82.
- 20. Fumi AL, Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008; 42(3): 408-12.